Aries Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 10-12-2024
- Paid Up Capital ₹ 8.72 M
as on 10-12-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 4.50 M
as on 10-12-2024
- Revenue 22.10%
(FY 2022)
- Profit 55.95%
(FY 2022)
- Ebitda 83.24%
(FY 2022)
- Net Worth -71.10%
(FY 2022)
- Total Assets 2.77%
(FY 2022)
About Aries Drugs
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.72 M.
The company has closed loans amounting to ₹4.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Amit Agarwal, Hari Agarwal, Madan Agarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232UR2005PTC007478
- Company No.
007478
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Apr 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Udham Singh Nagar, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Aries Drugs Private Limited offer?
Aries Drugs Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Nutraceuticals & Dietary Supplements, Nutraceuticals, Fresh, Dried & Preserved Fruits, Fresh Fruits.
Who are the key members and board of directors at Aries Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Agarwal  | Managing Director | 04-Apr-2005 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Hari Agarwal | Director | 21-Jan-2019 | Current |
| Madan Agarwal | Director | 02-May-2024 | Current |
| Ronak Agrawal | Director | 02-May-2024 | Current |
Financial Performance of Aries Drugs.
Aries Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 22.1% increase. The company also saw a substantial improvement in profitability, with a 55.95% increase in profit. The company's net worth observed a substantial decline by a decrease of 71.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aries Drugs?
Unlock access to Aries Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 18 Jul 2008 | ₹4.50 M | Satisfied |
How Many Employees Work at Aries Drugs?
Aries Drugs has a workforce of 21 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aries Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aries Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
